JDP Therapeutics went through a challenging and unique journey from product conception to FDA approval and being acquired in 2019. It did not involve professional investors because of their constant rejections. However this led to the huge investment return for its angel investors that is significantly higher than industry norm. JDP’s lead product is now on the market saving lives.